To know more about 57357 Covid-19 Clinic
Click here
314145

Outpatient Department

  • 19057
  • (202) 25351500

Day Treatment Unit

Overview

  • Day Treatment Unit is an open area at Children’s Cancer Hospital Egypt 57357 that provides comprehensive high quality and safe ambulatory care for pediatric oncology patients visiting both Solid Tumors and Hematology Outpatient Clinics.
  • Day Treatment Units serve an average number of 5000 patients per month.

All Day Treatment units are centralized and located at 1st floor.

Total number of 66 recliners for Chemotherapy or IV fluids administration, labs follow up, supportive Anti-Biotics and blood transfusion.

Working Hours: 24 hours a day, seven days a week, 365 days a year.

  1. Day Treatment Unit for Chemotherapy.
  2. Supportive Day Treatment for low risk fever neutropenic patients, follow up outpatients and blood transfusion.
  3. Private Care Unit (PCU).
  4. Take-Home Oral Medication Day Treatment Pharmacy.
  5. Patient Assessment Room.
  6. Patient Cannulation Room.
Day Treatment Unit for ChemotherapySupportive
Day Treatment Unit
Private
Care Unit
Dome 1 & 2
12 Recliners
12 Recliners11 Rooms
Dome A & B
17 Recliners
Dome C & D
14 Recliners
(1 Stretcher included)
  1. Patient assessment.
  2. Patient cannulation.
  3. Intravenous Chemotherapy administration.
  4. Intravenous fluid administration.
  5. Blood and platelets transfusion.
  6. Supportive care as Antibiotics and Granulocyte Colony-Stimulating Factor.
  7. Patient monitoring and follow-up.

Internal Relationships/Environmental Considerations:

  • Privacy:
    • Optimum visual and acoustic privacy for patients during resident daily clinical rounds and chemotherapy administration.
    • Privacy is one of the most important control factors affecting sound transmission between rooms; that’s a critical design consideration.

  • Environment:
  • Traffic in the patient administration area will be minimized, in order to reduce noise and confusion frequently experienced by patients.


  • Security:
    • Access to the component for patients and visitors will be through one door only.
    • Adjustable beds and nightstands.
    • Nurse Call system.
    • Individual television.
    • Patient meals as per their request.
    • Well-equipped rooms offer patients the necessary supervision, and comfort through the day, without the hassle of an overnight stay.

Criteria of Admission:

  • Adolescents suffering from anorexia, depression or confusion.
  • Bone Tumors especially amputated patients.
  • Nursing Infants.

Queuing system connecting, serving both Hematology and Solid Clinics and categorizing files acc. to Duration of Chemotherapy Infusion.

(Organizing patients’ admission at Day Treatment Chemotherapy Unit)

Solid Tumors
Ewing’s Sarcoma (ES)Low Grade Glioma (LGG)
Osteosarcoma (OS)High Grade Glioma (HGG)
Neuroblastoma (NB)Nasopharyngeal Carcinoma (NPC)
Hepatoblastoma (HB)Ependymoma
Medulloblastoma (MB)Choroid Plexus
Infantile MedualloblastomaNon-Germinoma Germ Cell Tumors
Retinoblastoma (RB)Germ Cell Tumors (GCT)
Renal Tumors (WT)Fibromatosis
Rhabdomyosarcoma (RMS)Relapse ES “Salvage”
Non-Rhabdomyosarcoma (Non-RMS)Relapse WT “Salvage”
Infantile HemangiomaR-ICE “Salvage”

Hematology
Acute Lymphoblastic Leukemia (ALL)Juvenile Myelomonocytic Leukemia (JMML)
Old Hodgkin's Lymphoma (HL)Non-Hodgkin’s Lymphoma (NHL)
EuroNet Hodgkin's LymphomaDiffuse Large B-Cell Lymphoma
Langerhans Cell Histocytosis (LCH)Hemophagocytic Lymphohistocytosis (HLH)
Relapsed R-16Anaplastic Large Cell Lymphoma (ALCL)
Relapsed R-DHAP for Refractory HL and NHLRelapsed FLAG/M
Immunoglobins for Bone Marrow
Transplantation and Maintenance Patients
Castleman Disease
Acute Myeloid Leukemia AML M3 (APL)
  • Clinical daily rounds for Continuing Long Infusions Chemotherapy.
  • Ordering investigations for patients coming from home to Day Treatment Units for prescheduled chemotherapy.
  • Follow up lab results & clinical examine to ensure that the patient is fit for chemotherapy.
  • Activating the inactive chemotherapy ordered by the primary on Power Chart Oncology.
  • Modifying technical errors related to Oncology Power chart orders.
  • Monitoring all patients with history of hypersensitivity to a specific chemotherapy e.g. (Asparaginase E.Coli, Carboplatin, etc.).
  • Observing all patients taking chemotherapy having potency to develop hypersensitivity reactions e.g. (Rituximab, Brentuximab, Aspraginase E.Coli, ImmunoGlobins, etc.).
  • Documentation of any hypersensitivity reactions or any interventions that occur during therapy.
  • Prescribe Take Home Medications for patients with a newly developed complain during Day Treatment accommodation.